As blue­bird makes com­mer­cial progress in Eu­rope, US ap­pli­ca­tion for Zyn­te­glo suf­fers de­lay

Af­ter shock­ing Wall Street with a $1.8 mil­lion price tag for its gene ther­a­py Zyn­te­glo in Eu­rope — blue­bird bio on Tues­day re­vealed that it now ex­pects to com­plete its US ap­pli­ca­tion to mar­ket the be­ta-tha­lassemia treat­ment in the Unit­ed States on­ly by the sec­ond half of the year, ver­sus its pre­vi­ous es­ti­mate of the first half of 2020.

The one-shot ther­a­py, al­so called Lenti­Glo­bin, is en­gi­neered to help pa­tients with the rare in­her­it­ed blood dis­or­der — who need reg­u­lar blood trans­fu­sions and have no match­ing donor for a stem cell trans­plant — be­come trans­fu­sion-in­de­pen­dent.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER